Wisconsin Alumni Research Foundation

Paul J Bertics

Richard A Proctor

Nicholas Lawrence Abbott

Donald T Witiak

Brian H Clare

Kirk Jeffrey Hogan

Kathleen Schell

Yingsheng Zhang

Loren C Denlinger

A method for differentiating between a post-translationally modified peptide and a peptide contained in a sample, comprising: (a) contacting the sample with a peptide attachment surface to create a peptidized surface, wherein the sample includes at least one functional group; (b) contacting the peptidized surface with a recognition reagent that selectively binds or forms a complex with the post-translationally modified peptide in the sample to provide an incubated surface; and (c) contacting a liquid crystal with the incubated surface and detecting presence of post-translationally modified peptide in the sample with the liquid crystal.

Detection of post-translationally modified peptides with liquid crystals

A method of assaying nucleotide receptor P2Xpore activity in white blood cells contained within a mixed cell sample is provided comprising labeling white blood cells with a white blood cell-specific label; depolarizing the labeled white blood cells with an isotonic depolarizing solution; contacting the labeled white blood cells with dye and a P2Xagonist in an amount sufficient to activate P2Xpore activity; contacting the labeled white blood cells with a divalent cation in an amount sufficient to deactivate P2Xpore activity; and analyzing dye uptake whereby P2Xpore activity is quantified by the amount of dye taken up in labeled white blood cells treated with the P2Xagonist relative to labeled white blood cells in the absence of said P2Xagonist, said P2Xpore activity being corrected for sample age and by subtraction of P2Xpore activity contributed by nonviable white blood cells.

Functional genomic pore assay for mixed cell populations

A method of rapidly assaying nucleotide receptor P2Xpore activity in white blood cells contained within a blood sample. A method according to the invention includes the steps of: (a) labeling the white blood cells with a white blood cell-specific label; (b) depolarizing the labeled white blood cells with an isotonic depolarizing solution; (c) contacting the labeled white blood cells with a dye and a P2Xagonist in an amount sufficient to activate nucleotide receptor P2Xpore activity; (d) contacting the labeled white blood cells with a divalent cation in an amount sufficient to deactivate nucleotide receptor P2Xpore activity; and (e) analyzing dye uptake in labeled white blood cells whereby nucleotide receptor P2Xpore activity is quantified by the amount of dye taken up in labeled white blood cells treated with P2Xagonist relative to labeled white blood cells in the absence of P2Xagonist.

White blood cell functional assay

Matrix metalloproteinase inhibitors and method of using same

Peptoid compounds of Formula I and Formula II are disclosed

A method for reducing the TNF-alpha in mammals with cerebral malaria comprising the administration of 2-methylthio-ATP or 2-chloro-ATP.

Method reducing TNF-alpha in mammals with cerebral malaria

A method of treating a mammal exposed to endotoxin in order to reduce the detrimental effects of said endotoxin, comprising administering to said mammal a therapeutically effective amount of a 2-halo-adenosine nucleotide analog. 2-Cloro-ATP is the preferred species of the 2-halo-adenosine nucleotide. The nucleotide used in this treatment inhibits lipo-polysaccharide-induced GTPase activity.

Method of treating endotoxin effects with 2-haloadenosine nucleotide

A method of treating mammals to reduce the deleterious effects of endotoxin and endotoxic shock mediators comprising administering a therapeutic amount of a 2-alkylthio-adenosine-5'-nucleotide. The preferred compound is 2-methylthio-adenosine-5'-triphosphate. The nucleotide used in this treatment inhibits lipopolysaccharide-induced GTPase activity.

Growing community of inventors

Oregon, WI, United States of America

Paul J Bertics